<p>Catherine Ronet and Mary-Anne Hartley of the University of Lausanne in Switzerland will target a naturally occurring RNA virus in Leishmania parasites (LRV) that not only aids parasite survival, but also causes a destructive inflammatory response in humans. They will develop and refine a LRV diagnostic device and formulate the virus as a vaccine candidate for the prevention and treatment of the leishmaniasis.</p>


Catherine Ronet and Mary-Anne Hartley of the University of Lausanne in Switzerland will target a naturally occurring RNA virus in Leishmania parasites (LRV) that not only aids parasite survival, but also causes a destructive inflammatory response in humans. They will develop and refine a LRV diagnostic device and formulate the virus as a vaccine candidate for the prevention and treatment of the leishmaniasis.